FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1565-1566 December 7, 1995 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Multiagent chemotherapy including anthracyclines can induce long-term disease-free survival in 40 to 45 percent of patients with intermediate-grade, aggressive non-Hodgkin's lymphoma. The other 55 to 60 percent of patients either do not have complete remission or have relapses, necessitating further treatment.¹ In this issue of the Journal, Philip et al.² describe the Parma study, in which patients with relapses of chemotherapy-sensitive, aggressive non-Hodgkin's lymphoma were randomly assigned to receive either conventional salvage chemotherapy or high-dose chemotherapy and autologous bone marrow transplantation. After a median follow-up of 63 months, the event-free survival among patients in the conventional-treatment group was 12 percent, . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.